Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Search

Page Path
HOME > Search
16 "Hoon-Kyo Kim"
Filter
Filter
Article category
Keywords
More +
Publication year
More +
Authors
More +
Funded articles
Original Article
General
The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yun, Byung-Ho Nam, Dae Young Zang
Cancer Res Treat. 2025;57(1):39-46.   Published online July 10, 2024
DOI: https://doi.org/10.4143/crt.2024.421
AbstractAbstract PDFPubReaderePub
Purpose
The Korean Cancer Study Group (KCSG) is a nationwide cancer clinical trial group dedicated to advancing investigator-initiated trials (IITs) by conducting and supporting clinical trials. This study aims to review IITs conducted by KCSG and quantitatively evaluate the survival and financial benefits of IITs for patients.
Materials and Methods
We reviewed IITs conducted by KCSG from 1998 to 2023, analyzing progression-free survival (PFS) and overall survival (OS) gains for participants. PFS and OS benefits were calculated as the difference in median survival times between the intervention and control groups, multiplied by the number of patients in the intervention group. Financial benefits were assessed based on the cost of investigational products provided.
Results
From 1998 to 2023, KCSG conducted 310 IITs, with 133 completed and published. Of these, 21 were included in the survival analysis. The analysis revealed that 1,951 patients in the intervention groups gained a total of 2,558.4 months (213.2 years) of PFS and 2,501.6 months (208.5 years) of OS, with median gains of 1.31 months in PFS and 1.58 months in OS per patient. When analyzing only statistically significant results, PFS and OS gain per patients was 1.69 months and 3.02 months, respectively. Investigational drug cost analysis from six available IITs indicated that investigational products provided to 252 patients were valued at 10,400,077,294 won (approximately 8,046,481 US dollars), averaging about 41,270,148 won (approximately 31,930 US dollars) per patient.
Conclusion
Our findings, based on analysis of published research, suggest that IITs conducted by KCSG led to survival benefits for participants and, in some studies, may have provided financial benefits by providing investment drugs.
  • 2,015 View
  • 154 Download
Close layer
Obituary
In Memoriam: Waun Ki Hong, M.D. (August 13, 1942-January 2, 2019)
Hoon-Kyo Kim
Cancer Res Treat. 2019;51(2):415-416.   Published online March 18, 2019
DOI: https://doi.org/10.4143/crt.2019.149
PDFPubReaderePub

Citations

Citations to this article as recorded by  
  • Waun Ki Hong, MD, D.M.Sc (Hon) (1942–2019): A Mentor Who Left Behind a Legacy for Generations to Come
    Hyun Cheol Chung
    Yonsei Medical Journal.2020; 61(7): 557.     CrossRef
  • 6,108 View
  • 191 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Original Articles
Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer
Dong-Wan Kim, Hoon-Gu Kim, Joo-Hang Kim, Keunchil Park, Hoon-Kyo Kim, Joung Soon Jang, Bong-Seog Kim, Jin-Hyoung Kang, Kyung Hee Lee, Sang-We Kim, Hun Mo Ryoo, Jin-Soo Kim, Ki Hyeong Lee, Jung Hye Kwon, Jin-Hyuk Choi, Sang Won Shin, Seokyung Hahn, Dae Seog Heo
Cancer Res Treat. 2019;51(1):119-127.   Published online March 12, 2018
DOI: https://doi.org/10.4143/crt.2018.019
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This randomized phase III study was designed to compare the efficacy and safety of irinote-can plus cisplatin (IP) over etoposide plus cisplatin (EP) in Korean patients with extensive-disease small-cell lung cancer (SCLC).
Materials and Methods
Patients were randomly assigned to receive IP, composed of irinotecan 65 mg/m2 intravenously on days 1 and 8+cisplatin 70 mg/m2 intravenously on day 1 every 3 weeks, or EP, composed of etoposide 100 mg/m2 intravenously on days 1, 2, 3+cisplatin 70 mg/m2 intravenously on day 1, every 3 weeks for a maximum of six cycles, until disease progression, or until unacceptable toxicity occurred. The primary endpoint was overall survival.
Results
A total of 362 patients were randomized to IP (n=173) and EP (n=189) arms. There were no significant differences between IP and EP arms for the median overall survival (10.9 months vs. 10.3 months, p=0.120) and the median progression-free survival (6.5 months vs. 5.8 months, p=0.115). However, there was a significant difference in response rate (62.4% vs. 48.2%, p=0.006). The pre-planned subgroup analyses showed that IP was associated with longer overall survival in male (11.3 months vs. 10.1 months, p=0.036), < 65 years old (12.7 months vs. 11.3 months, p=0.024), and Eastern Cooperative Oncology Group performance status 0/1 (12.4 months vs. 10.9 months, p=0.040) patient groups. The severity of treatment-related adverse events such as grade 3/4 anemia, nausea and diarrhea was more frequent in patients treated with IP.
Conclusion
The IP chemotherapy did not significantly improve the survival compared with EP chemotherapy in Korean patients with extensive-disease SCLC.

Citations

Citations to this article as recorded by  
  • Factors associated with posttraumatic stress and anxiety among the parents of babies admitted to neonatal care: a systematic review
    Reem Malouf, Sian Harrison, Victoria Pilkington, Charles Opondo, Chris Gale, Alan Stein, Linda S. Franck, Fiona Alderdice
    BMC Pregnancy and Childbirth.2024;[Epub]     CrossRef
  • Real world results of locally advanced and metastatic lung cancer patients treated with platinum doublet chemotherapy in first line: Moroccan cohort
    Hassan Abdelilah Tafenzi, Farah Choulli, Edwin Kelly Haag, Anass Baladi, Ismail Essaadi, Rhizlane Belbaraka
    Translational Oncology.2024; 47: 102015.     CrossRef
  • Clinical Benefits of new Systemic Therapy for Small‐Cell Lung Cancer Over Two Decades: A Cross‐Sectional Study
    Yuejing Chen, Honghong Liu, Shaohua Bai, Xuejiao Han, Fei Jin, Bo Cui
    The Clinical Respiratory Journal.2024;[Epub]     CrossRef
  • Camptothecin and Its Derivatives from Traditional Chinese Medicine in Combination with Anticancer Therapy Regimens: A Systematic Review and Meta-Analysis
    Paul O. Odeniran, Paradise Madlala, Nompumelelo P. Mkhwanazi, Mahmoud E. S. Soliman
    Cancers.2024; 16(22): 3802.     CrossRef
  • Effect of trilaciclib administered before chemotherapy in patients with extensive-stage small-cell lung cancer: A pooled analysis of four randomized studies
    Ying Liu, Lin Wu, Dingzhi Huang, Qiming Wang, Chen Yang, Li Zhou, Shuguang Sun, Xiaomei Jiang, Ying Cheng
    Cancer Treatment and Research Communications.2024; 42: 100869.     CrossRef
  • Efficacy and toxicity profile of first‐line treatment for extensive‐stage small cell lung cancer: A Bayesian network meta‐analysis
    Guo Lin, Zhuoran Yao, Kai Kang, Hui Wang, Ren Luo, You Lu
    Cancer Medicine.2023; 12(9): 10230.     CrossRef
  • Therapeutic strategy analysis of patients with advanced stage high‐grade neuroendocrine cervical cancer: A real‐world multicenter study
    Yuanyuan Zhang, Yi Huang, Suiyu Luo, Lin Li, Hongying Yang, Ziyi Wang, Yongmei Peng, Manni Huang, Jusheng An, Xi Yang, Jing Wang, Chunmei Li, Lingying Wu
    International Journal of Gynecology & Obstetrics.2022; 158(3): 722.     CrossRef
  • Systematic evaluation of the efficacy‐effectiveness gap of systemic treatments in extensive disease small cell lung cancer
    Christine M. Cramer‐van der Welle, Franz M. N. H. Schramel, Bas J. M. Peters, John W. G. van Putten, Olaf H. Klungel, Harry J. M. Groen, Ewoudt M. W. van de Garde
    Pharmacoepidemiology and Drug Safety.2021; 30(4): 445.     CrossRef
  • Treatment Outcomes of 9,994 Patients With Extensive-Disease Small-Cell Lung Cancer From a Retrospective Nationwide Population-Based Cohort in the Korean HIRA Database
    Jung Soo Lee, Seoree Kim, Soo-Yoon Sung, Yeo Hyung Kim, Hyun Woo Lee, Ji Hyung Hong, Yoon Ho Ko
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
    Koichi Ando, Ryo Manabe, Yasunari Kishino, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori, Tsukasa Ohnishi, Hironori Sagara
    Current Oncology.2021; 28(2): 1094.     CrossRef
  • Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study
    Seo Ree Kim, Ji Hyung Hong, Soo-Yoon Sung, Yeo Hyung Kim, Sang Hoon Chun, Hyun Woo Lee, Jung Soo Lee, Yoon Ho Ko
    BMC Cancer.2021;[Epub]     CrossRef
  • Clinical significance of the cachexia index in patients with small cell lung cancer
    Se-Il Go, Mi Jung Park, Gyeong-Won Lee
    BMC Cancer.2021;[Epub]     CrossRef
  • Sevens Cases of Neuroendocrine Carcinoma of the Nasal and Paranasal Sinuses
    Ichiro Sekine, Kan Kishibe, Miki Takahara, Hiroaki Katada, Tatsuya Hayashi, Yasuaki Harabuchi
    Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology).2021; 60(2): 169.     CrossRef
  • Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion
    Millie Das, Sukhmani K. Padda, Jared Weiss, Taofeek K. Owonikoko
    Advances in Therapy.2021; 38(11): 5431.     CrossRef
  • Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
    Ellen Cusano, Chelsea Wong, Eddy Taguedong, Marcus Vaska, Tasnima Abedin, Nancy Nixon, Safiya Karim, Patricia Tang, Daniel Y. C. Heng, Doreen Ezeife
    Current Oncology.2021; 28(6): 4894.     CrossRef
  • Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive‐stage disease small cell lung cancer: Results from a randomized controlled trial
    Gyeong‐Won Lee, Se‐Il Go, Dong‐Wan Kim, Hoon‐Gu Kim, Joo‐Hang Kim, Ho Jung An, Joung Soon Jang, Bong‐Seog Kim, Seokyung Hahn, Dae Seog Heo
    Thoracic Cancer.2020; 11(1): 62.     CrossRef
  • IRS2 Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer
    Mi-Sook Lee, Kyungsoo Jung, Ji-Young Song, Min-Jung Sung, Sung-Bin Ahn, Boram Lee, Doo-Yi Oh, Yoon-La Choi
    Molecular Therapy - Oncolytics.2020; 16: 188.     CrossRef
  • Etoposide and cisplatin versus irinotecan and cisplatin as the first‐line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study
    Panpan Zhang, Jie Li, Jian Li, Xiaotian Zhang, Jun Zhou, Xicheng Wang, Zhi Peng, Lin Shen, Ming Lu
    Cancer.2020; 126(S9): 2086.     CrossRef
  • Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis
    Hao Chen, Nobuyuki Horita, Kentaro Ito, Hideyuki Nagakura, Yu Hara, Nobuaki Kobayash, Masaki Yamamoto, Makoto Kudo, Takeshi Kaneko
    Therapeutic Advances in Medical Oncology.2020;[Epub]     CrossRef

  • A Retrospective Cohort Study on Pretreated Neutrophil-to-Lymphocyte Ratio and Prognosis of Small Cell Lung Cancer: Evidence of Effect Modification by Chemotherapy Regimen


    Feiwen Liu, Shaozhang Zhou, Liping Tan, Huiqin Jiang, Yucong Huang
    Cancer Management and Research.2020; Volume 12: 10341.     CrossRef
  • Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer
    Ting Zhou, Zhonghan Zhang, Fan Luo, Yuanyuan Zhao, Xue Hou, Tingting Liu, Kai Wang, Hongyun Zhao, Yan Huang, Li Zhang
    JAMA Network Open.2020; 3(10): e2015748.     CrossRef
  • Thérapie ciblée et immunothérapie du cancer bronchique à petites cellules
    J.-L. Pujol, C. Goze, C. Pujol, B. Roch
    Revue des Maladies Respiratoires Actualités.2019; 11(3): 315.     CrossRef
  • Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis
    Fei Xu, Xiaoli Ren, Yuan Chen, Qianxia Li, Ruichao Li, Yu Chen, Shu Xia
    BMC Cancer.2018;[Epub]     CrossRef
  • Traitement médical du cancer bronchique à petites cellules : peut-on sortir de l’aire du cisplatine–étoposide ?
    Jean-Louis Pujol, Benoît Roch, Camille N. Pujol, Catherine Goze
    Bulletin du Cancer.2018;[Epub]     CrossRef
  • 13,150 View
  • 528 Download
  • 30 Web of Science
  • 24 Crossref
Close layer
Adopting Advance Directives Reinforces Patient Participation in End-of-Life Care Discussion
Ji Hyung Hong, Jung Hye Kwon, Il Kyu Kim, Jin Hee Ko, Yi-Jin Kang, Hoon-Kyo Kim
Cancer Res Treat. 2016;48(2):753-758.   Published online October 14, 2015
DOI: https://doi.org/10.4143/crt.2015.281
AbstractAbstract PDFPubReaderePub
Purpose
In Korea, most terminal cancer patients have still not been included in end-of-life (EOL) discussions. The purpose of this study was to evaluate the proportion of patients participating in EOL discussions after adopting advance directives.
Materials and Methods
Medical records of 106 hospice patients between July 2012 and February 2013 were reviewed retrospectively. The proportion of patient participation in EOL discussions, barriers, and favorable factors for completion of advance directives, as well as outcomes of advance directives were evaluated.
Results
Patient participation in EOL discussion had increased from 16/53 (30%) to 27/53 (51%) since adopting advance directives (p < 0.001). Median time between completion of an advance directive and death increased from 8 days (range, 0 to 22 days) to 14.5 days (range, 0 to 47 days). Patients’ poor condition after late referral was the main barrier to missing EOL discussions; however, family members’ concerns about patient’s distress was also a main reason for excluding the patient from EOL discussions. In univariate analysis, patient age, education status, and time from diagnosis to completion of an advance directive influenced advance directive completion favorably. Following multivariate analysis, higher education and periods of more than 2 years from diagnosis to completion of an advance directive remained favorable (odds ratio [OR], 9.586, p=0.024 and OR, 70.312; p=0.002). Preferences of all patients regarding cardiopulmonary resuscitation or hemodialysis were carried out by physicians. Orders for nutrition and palliative sedation showed discordance, with concordance rates of 74.2% and 51.6%, respectively.
Conclusion
Our results suggested that the use of advance directive promote patient participation in EOL discussion.

Citations

Citations to this article as recorded by  
  • Participation and Influencing Factors in the Decision-Making of Life-Sustaining Treatment: A Focus on Deceased Patients with Hematologic Neoplasms
    Jae Eun Jang, Jeong Moon Ryu, Min Hee Heo, Do Eun Kwon, Ji Yeon Seo, Dong Yeon Kim
    The Korean Journal of Hospice and Palliative Care.2023; 26(2): 69.     CrossRef
  • Discussing POLST-facilitated hospice care enrollment in patients with terminal cancer
    Ho Jung An, Hyun Jeong Jeon, Sang Hoon Chun, Hyun Ae Jung, Hee Kyung Ahn, Kyung Hee Lee, Min-ho Kim, Ju Hee Kim, Jaekyung Cheon, Su-Jin Koh
    Supportive Care in Cancer.2022; 30(9): 7431.     CrossRef
  • A quantitative study of nurses perception to advance directive in selected private and public secondary healthcare facilities in Ibadan, Nigeria
    Oluwaseyi Emiola Ojedoyin, Ayodele Samuel Jegede
    BMC Medical Ethics.2022;[Epub]     CrossRef
  • Influence of advance directives on reducing aggressive measures during end-of-life cancer care: A systematic review
    Lillian Ponchio e Silva Marchi, Martins Fideles dos Santos Neto, Júlia de Pauli Moraes, Carlos Eduardo Paiva, Bianca Sakamoto Ribeiro Paiva
    Palliative and Supportive Care.2021; 19(3): 348.     CrossRef
  • A National Study of Life-Sustaining Treatments in South Korea: What Factors Affect Decision-Making?
    So-Youn Park, Bomyee Lee, Jeong Yeon Seon, In-Hwan Oh
    Cancer Research and Treatment.2021; 53(2): 593.     CrossRef
  • The Situation of Life-Sustaining Treatment One Year after Enforcement of the Act on Decisions on Life-Sustaining Treatment for Patients at the End-of-Life in Korea: Data of National Agency for Management of Life-Sustaining Treatment
    Ha Yeon Lee, Hwa Jung Kim, Jung Hye Kwon, Sun Kyung Baek, Young-Woong Won, Yu Jung Kim, Su Jin Baik, Hyewon Ryu
    Cancer Research and Treatment.2021; 53(4): 897.     CrossRef
  • Preparation and Practice of the Necessary Documents in Hospital for the “Act on Decision of Life-Sustaining Treatment for Patients at the End-of-Life”
    Sun Kyung Baek, Hwa Jung Kim, Jung Hye Kwon, Ha Yeon Lee, Young-Woong Won, Yu Jung Kim, Sujin Baik, Hyewon Ryu
    Cancer Research and Treatment.2021; 53(4): 926.     CrossRef
  • Modifiable Factors Associated with the Completion of Advance Treatment Directives in Hematologic Malignancy: A Patient–Caregiver Dyadic Analysis
    JinShil Kim, Jinny Park, Mee Ok Lee, Eun Young Park, Seongkum Heo, Jae Lan Shim
    Journal of Palliative Medicine.2020; 23(5): 611.     CrossRef
  • Nurses' perspectives on advance directives before the establishment of the new well-dying law in Korea: A mixed methods study
    Youn-Jung Son, JiYeon Choi, Jung-Won Ahn
    Applied Nursing Research.2020; 51: 151187.     CrossRef
  • Hospital Nurses’ Perception of Death and Self-Reported Performance of End-of-Life Care: Mediating Role of Attitude towards End-of-Life Care
    Hyo-Jin Park, Yun-Mi Lee, Mi Hwa Won, Sung-Jun Lim, Youn-Jung Son
    Healthcare.2020; 8(2): 142.     CrossRef
  • Implication of the Life-Sustaining Treatment Decisions Act on End-of-Life Care for Korean Terminal Patients
    Jung Sun Kim, Shin Hye Yoo, Wonho Choi, Yejin Kim, Jinui Hong, Min Sun Kim, Hye Yoon Park, Bhumsuk Keam, Dae Seog Heo
    Cancer Research and Treatment.2020; 52(3): 917.     CrossRef
  • Advance care planning in Asian culture
    Shao-Yi Cheng, Cheng-Pei Lin, Helen Yue-lai Chan, Diah Martina, Masanori Mori, Sun-Hyun Kim, Raymond Ng
    Japanese Journal of Clinical Oncology.2020; 50(9): 976.     CrossRef
  • Family Members' Experience of Discussions on End-of-Life Care in Nursing Homes in Japan
    Hiroki Kato, Keiko Tamura
    Journal of Hospice & Palliative Nursing.2020; 22(5): 401.     CrossRef
  • Efficacy of a Decision Aid Consisting of a Video and Booklet on Advance Care Planning for Advanced Cancer Patients: Randomized Controlled Trial
    Young Ho Yun, EunKyo Kang, Sohee Park, Su-Jin Koh, Ho-Suk Oh, Bhumsuk Keam, Young Rok Do, Won Jin Chang, Hyun Sik Jeong, Eun Mi Nam, Kyung Hae Jung, Hak Ro Kim, Jiyeon Choo, Jihye Lee, Jin-Ah Sim
    Journal of Pain and Symptom Management.2019; 58(6): 940.     CrossRef
  • Effect of the duration of hospice and palliative care on the quality of dying and death in patients with terminal cancer: A nationwide multicentre study
    J.Y. Choi, K.A. Kong, Y.J. Chang, H.J. Jho, E.M. Ahn, S.K. Choi, S. Park, M.K. Lee
    European Journal of Cancer Care.2018; 27(2): e12771.     CrossRef
  • End-of-Life Care and Discussions in Japanese Geriatric Health Service Facilities: A Nationwide Survey of Managing Directors’ Viewpoints
    Asako Kanoh, Yoshiyuki Kizawa, Satoru Tsuneto, Shoji Yokoya
    American Journal of Hospice and Palliative Medicine®.2018; 35(1): 83.     CrossRef
  • Does special education in palliative medicine make a difference in end-of-life decision-making?
    Reetta P. Piili, Juho T. Lehto, Tiina Luukkaala, Heikki Hinkka, Pirkko-Liisa I. Kellokumpu-Lehtinen
    BMC Palliative Care.2018;[Epub]     CrossRef
  • A Concept Analysis of End-of-life Discussions with Cancer Patients
    Midori Kadowaki
    Journal of Japan Academy of Nursing Science.2016; 36: 263.     CrossRef
  • 11,803 View
  • 144 Download
  • 16 Web of Science
  • 18 Crossref
Close layer
The Efficacy of External Beam Radiotherapy for Airway Obstruction in Lung Cancer Patients
Jeong Won Lee, Jong Hoon Lee, Hoon-Kyo Kim, Byoung Yong Shim, Ho Jung An, Sung Hwan Kim
Cancer Res Treat. 2015;47(2):189-196.   Published online September 12, 2014
DOI: https://doi.org/10.4143/crt.2013.261
AbstractAbstract PDFPubReaderePub
Purpose
The objective of this study was to evaluate external beam radiotherapy (EBRT) in lung cancer patients who suffer from airway obstruction. Materials and Methods Medical data of 95 patients with a lung mass that obstructed the airway and received EBRT for it were analyzed. Fifty-nine patients (62.1%) had non-small cell lung cancer and 36 patients (37.9%) had small cell lung cancer. Radiotherapy was given at 8 to 45 Gy (median, 30 Gy) in 1 to 15 fractions (median, 10 fractions). The response to EBRT was assessed through changes in radiographic findings and/or subjective symptoms between before and after EBRT. The median follow-up duration was 124 days. The primary end point was the airway-obstruction resolving rate after EBRT. The secondary end points were patient survival and toxic effects of EBRT. Results Improvement of airway obstruction after EBRT on chest X-ray was achieved in 75 of 95 patients (78.9%). The median time for resolving the radiologic findings and/or symptoms of airway obstruction after EBRT was 7 days (range, 1 to 76 days). The 1-year survival rate was significantly higher in responders than non-responders (12.5% vs. 0.0%, p < 0.001). The biologically effective dose of ≥ 39 Gyα/β=10 (p < 0.01) and the longest obstructive lesion of < 6 cm (p=0.04) were significantly associated with a good response to EBRT in resolving the airway obstruction. No one had grade 3 or higher acute and chronic toxicities. Conclusion EBRT is an effective treatment in relieving airway obstruction without severe toxicities in lung cancer patients.

Citations

Citations to this article as recorded by  
  • Malignant Central Airway Obstruction
    Erik Vakil, Melissa Wang
    Clinics in Chest Medicine.2025;[Epub]     CrossRef
  • External Beam Radiotherapy for Malignant Central Airway Obstruction in a Remote Rural Patient: A Case Study
    Eoin Collins, Druva Mitra, Scott Carruthers
    Case Reports in Oncology.2024; 17(1): 1301.     CrossRef
  • Mid-treatment adaptive planning during thoracic radiation using 68 Ventilation-Perfusion Positron emission tomography
    Nicholas Bucknell, Nicholas Hardcastle, Roshini Gunewardena, Long Nguyen, Jason Callahan, David Ball, Lisa Selbie, Tomas Kron, Guy-Anne Turgeon, Michael S. Hofman, Shankar Siva
    Clinical and Translational Radiation Oncology.2023; 40: 100599.     CrossRef
  • Efficacy and Survival after Palliative Radiotherapy for Malignant Pulmonary Obstruction
    Adam G. Johnson, Michael H. Soike, Michael K. Farris, Ryan T. Hughes
    Journal of Palliative Medicine.2022; 25(1): 46.     CrossRef
  • Therapeutic Rigid Bronchoscopy Intervention for Malignant Central Airway Obstruction Improves Performance Status to Allow Systemic Treatment
    Edward Y.C. Lee, Annette M. McWilliams, Matthew R. Salamonsen
    Journal of Bronchology & Interventional Pulmonology.2022; 29(2): 93.     CrossRef
  • Malignant Central Airway Obstruction: What's New?
    Brian D. Shaller, Darius Filsoof, Jorge M. Pineda, Thomas R. Gildea
    Seminars in Respiratory and Critical Care Medicine.2022; 43(04): 512.     CrossRef
  • Combination of Palliative Thoracic Radiotherapy With Bevacizumab for Stage IV Nonsquamous NSCLC: Is There Any Impact of Time Interval on Survival?
    Weigang Xiu, Xiaotong Guo, Min Yu, Yanying Li, Yong Xu, Jiang Zhu, Jingjing Luo
    Clinical Medicine Insights: Oncology.2022;[Epub]     CrossRef
  • First-In-Human Computer-Optimized Endobronchial Ultrasound-Guided Interstitial Photodynamic Therapy for Patients With Extrabronchial or Endobronchial Obstructing Malignancies
    Nathaniel M. Ivanick, Emily R. Oakley, Rajesh Kunadharaju, Craig Brackett, David A. Bellnier, Lawrence M. Tworek, Sergei N. Kurenov, Sandra O. Gollnick, Alan D. Hutson, Theresa M. Busch, Gal Shafirstein
    JTO Clinical and Research Reports.2022; 3(10): 100372.     CrossRef
  • Electrospray Mediated Localized and Targeted Chemotherapy in a Mouse Model of Lung Cancer
    Paulius Ruzgys, Stephan Böhringer, Ayse Sila Dokumaci, Yvonne Hari, Christian M. Schürch, Frido Brühl, Stefan Schürch, Sönke Szidat, Carsten Riether, Saulius Šatkauskas, Thomas Geiser, David Hradetzky, Amiq Gazdhar
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Role of radiotherapy in the management of malignant airway obstruction
    Hoon Sik Choi, Bae Kwon Jeong, Hojin Jeong, In Bong Ha, Ki Mun Kang
    Thoracic Cancer.2020; 11(8): 2163.     CrossRef
  • Prospective Multicentered Safety and Feasibility Pilot for Endobronchial Intratumoral Chemotherapy
    Lonny Yarmus, Christopher Mallow, Jason Akulian, Cheng Ting Lin, David Ettinger, Russell Hales, Kinh Ranh Voong, Hans Lee, David Feller-Kopman, Roy Semaan, Kirk Seward, Momen M. Wahidi
    Chest.2019; 156(3): 562.     CrossRef
  • Functional airway obstruction observed with hyperpolarized 129Xenon‐MRI
    Erin J Song, Chris R Kelsey, Bastiaan Driehuys, Leith Rankine
    Journal of Medical Imaging and Radiation Oncology.2018; 62(1): 91.     CrossRef
  • Endobronchial brachytherapy in the management of lung malignancies: 20 years of experience in an Australian center
    Matthew C. Knox, Andrej Bece, Joseph Bucci, John Moses, Peter H. Graham
    Brachytherapy.2018; 17(6): 973.     CrossRef
  • 13,862 View
  • 92 Download
  • 19 Web of Science
  • 13 Crossref
Close layer
A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy
Hee Yeon Lee, Hoon-Kyo Kim, Kyung Hee Lee, Bong-Seog Kim, Hong Suk Song, Sung Hyun Yang, Joon Hee Kim, Yeul Hong Kim, Jong Gwang Kim, Sang-We Kim, Dong-Wan Kim, Si-Young Kim, Hee Sook Park
Cancer Res Treat. 2014;46(1):19-26.   Published online January 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.1.19
AbstractAbstract PDFPubReaderePub
PURPOSE
This study was conducted to evaluate the efficacy and safety of azasetron compared to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting.
MATERIALS AND METHODS
This study was a multi-center, prospective, randomized, double-dummy, double-blind and parallel-group trial involving 12 institutions in Korea between May 2005 and December 2005. A total of 265 patients with moderately and highly emetogenic chemotherapy were included and randomly assigned to either the azasetron or ondansetron group. All patients received azasetron (10 mg intravenously) and dexamethasone (20 mg intravenously) on day 1 and dexamethasone (4 mg orally every 12 hours) on days 2-4. The azasetron group received azasetron (10 mg orally) with placebo of ondansetron (orally every 12 hours), and the ondansetron group received ondansetron (8 mg orally every 12 hours) with placebo of azasetron (orally) on days 2-6.
RESULTS
Over days 2-6, the effective ratio of complete response in the azasetron and ondansetron groups was 45% and 54.5%, respectively (95% confidence interval, -21.4 to 2.5%). Thus, the non-inferiority of azasetron compared with ondansetron in delayed chemotherapy-induced nausea and vomiting was not proven in the present study. All treatments were well tolerated and no unexpected drug-related adverse events were reported. The most common adverse events related to the treatment were constipation and hiccups, and there were no differences in the overall incidence of adverse events.
CONCLUSION
In the present study, azasetron showed inferiority in the control of delayed chemotherapy-induced nausea and vomiting compared with ondansetron whereas safety profiles were similar between the two groups.

Citations

Citations to this article as recorded by  
  • Influence of ABCB1 genetic polymorphisms on the antiemetic response to ondansetron-based medication for cisplatin-based chemotherapy in South Indian cancer patients in a tertiary care hospital
    Ayyar Porkodi, Deepak Gopal Shewade, Goud Alladi Charanraj
    Current Issues in Pharmacy and Medical Sciences.2023; 36(3): 129.     CrossRef
  • Hiccups in Cancer Patients Receiving Chemotherapy: A Cross-Sectional Study
    Mevlüde Ergen, Fatma Arikan, Rüya Fırat Çetin
    Journal of Pain and Symptom Management.2021; 62(3): e85.     CrossRef
  • A Fast and Validated HPLC Method for the Simultaneous Analysis of Five 5-HT3 Receptor Antagonists via the Quantitative Analysis of Multicomponents by a Single Marker
    Fuchao Chen, Baoxia Fang, Peng Li, Sicen Wang, Amr M. Mahmoud
    International Journal of Analytical Chemistry.2021; 2021: 1.     CrossRef
  • Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis
    Vanessa Piechotta, Anne Adams, Madhuri Haque, Benjamin Scheckel, Nina Kreuzberger, Ina Monsef, Karin Jordan, Kathrin Kuhr, Nicole Skoetz
    Cochrane Database of Systematic Reviews.2021;[Epub]     CrossRef
  • Effectiveness of Steroid Rotation in a Japanese Patient with Hiccups Caused by Dexamethasone: a Case Report
    Hiroki Hosokawa, Hideaki Shimoda, Takayuki Ishii
    YAKUGAKU ZASSHI.2019; 139(4): 647.     CrossRef
  • Stability of azasetron-dexamethasone mixture for chemotherapy-induced nausea and vomiting administration
    Bao-Xia Fang, Fu-Chao Chen, Dan Zhu, Jun Guo, Lin-Hai Wang
    Oncotarget.2017; 8(63): 106249.     CrossRef
  • Gender Differences in Hiccup Patients: Analysis of Published Case Reports and Case-Control Studies
    Gyeong-Won Lee, Rock Bum Kim, Se Il Go, Hyun Seop Cho, Seung Jun Lee, David Hui, Eduardo Bruera, Jung Hun Kang
    Journal of Pain and Symptom Management.2016; 51(2): 278.     CrossRef
  • Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting
    Bishal Gyawali, Bishesh Sharma Poudyal, Mahesh Iddawela
    Journal of Global Oncology.2016; 2(3): 145.     CrossRef
  • Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review
    K. Jordan, F. Jahn, M. Aapro
    Annals of Oncology.2015; 26(6): 1081.     CrossRef
  • 12,294 View
  • 70 Download
  • 8 Web of Science
  • 9 Crossref
Close layer
Gemcitabine Plus Platinum Combination Chemotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Analysis
Sang Hoon Chun, Ji Eun Lee, Mi Hee Park, Jin-Hyoung Kang, Young Kyoon Kim, Young-Pil Wang, Jae Kil Park, Hoon-Kyo Kim
Cancer Res Treat. 2011;43(4):217-224.   Published online December 27, 2011
DOI: https://doi.org/10.4143/crt.2011.43.4.217
AbstractAbstract PDFPubReaderePub
PURPOSE
This study aimed to analyze the efficacy and toxicity of gemcitabine plus platinum chemotherapy for patients aged 70 years or older with advanced non-small-cell lung cancer (NSCLC).
MATERIALS AND METHODS
We reviewed the records of stage IIIB, IV NSCLC patients or surgically inoperable stage II, IIIA NSCLC patients who were aged 70 years or older when treated with gemcitabine (1,250 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) chemotherapy from 2001 to 2010 at Seoul St. Mary's Hospital, Uijeongbu St. Mary's Hospital and St. Vincent's Hospital. Gemcitabine was administered on days 1 and 8, and cisplatin or carboplatin was administered on day 1. Treatments were repeated every 3 weeks for a maximum of 4 cycles.
RESULTS
The median age of the 62 patients was 73.5 years (range, 70 to 84 years). Forty-one (66%) patients exhibited comorbidity. The mean number of treatment cycles was 3.9. The compared average relative dose intensity of gemcitabine plus platinum chemotherapy was 84.8%. The median progression-free survival and overall survival (OS) were 5.0 months and 9.4 months, respectively. Reduced Eastern Cooperative Oncology Group (ECOG) performance status (none vs. > or =1) and weight loss (<5% vs. > or =5%) after treatment were found to have a significant effect on OS (p=0.01).
CONCLUSION
Gemcitabine plus platinum chemotherapy is an effective treatment option with an acceptable level of toxicity in patients aged 70 years or older with good performance status in advanced NSCLC.

Citations

Citations to this article as recorded by  
  • Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
    Xue-Song Sun, Xiao-Hao Wang, Sai-Lan Liu, Dong-Hua Luo, Rui Sun, Li-Ting Liu, Shan-Shan Guo, Qiu-Yan Chen, Lin-Quan Tang, Hai-Qiang Mai
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • The safety and efficacy of cisplatin plus gemcitabine in recurrent ovarian cancer
    Yui Tomita, Toshiaki Saito, Masao Okadome, Takako Eto, Kazuya Ariyoshi, Kumi Shimamoto
    International Journal of Clinical Oncology.2014; 19(4): 662.     CrossRef
  • A cross-country review of data collected on non-small cell lung cancer (NSCLC) patients in cancer registries, databases, retrospective and non-randomized prospective studies
    Anna De Geer, Jennifer Eriksson, Henrik W. Finnern
    Journal of Medical Economics.2013; 16(1): 134.     CrossRef
  • Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer
    Anandi Sawant, Jessy Deshane, Joel Jules, Carnella M. Lee, Brittney A. Harris, Xu Feng, Selvarangan Ponnazhagan
    Cancer Research.2013; 73(2): 672.     CrossRef
  • Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways
    Anandi Sawant, Cara C. Schafer, Tong Huan Jin, Jaroslaw Zmijewski, Hubert M. Tse, Justin Roth, Zhihuan Sun, Gene P. Siegal, Victor J. Thannickal, Stefan C. Grant, Selvarangan Ponnazhagan, Jessy S. Deshane
    Cancer Research.2013; 73(22): 6609.     CrossRef
  • 11,551 View
  • 64 Download
  • 5 Crossref
Close layer
Prognostic Role of Rb, p16, Cyclin D1 Proteins in Soft Tissue Sarcomas
Byoung Yong Shim, Jinyoung Yoo, Yeon-Soo Lee, Young Sun Hong, Hoon-Kyo Kim, Jin-Hyoung Kang
Cancer Res Treat. 2010;42(3):144-150.   Published online September 30, 2010
DOI: https://doi.org/10.4143/crt.2010.42.3.144
AbstractAbstract PDFPubReaderePub
Purpose

The aim of this study was to determine the expressions of Rb, p16, and cyclin D1 in soft tissue sarcomas, and we also wanted to identify the prognostic factors according to the clinicalpathologic features.

Materials and Methods

We reviewed the charts and radiographic films of 66 sarcoma patients. Tissue samples were collected from these patients. Immunochemistry was performed using formalin-fixed, paraffin-embedded tissue samples to examine the expressions of p16, Rb, and cyclin D1 proteins.

Results

The median duration of overall survival was 47.8 months (range, 20.0 to 70.7 months) and the 5 years survival rate was 39%. As for the correlation between the degree of immunohistochemical staining for Rb protein and the histological tumor grades, there was a significant difference with a p-value of 0.019. However, no significant correlation was shown for p16 and cyclin D1. The overall survival duration of the Rb negative group (staining cell <20%) and the heterogeneous group (cell staining 20 to 80%) was 53.5±6.6 months and the overall survival duration of the Rb homogeneous group was 18.3±6.4 months, and there was a significant difference with a p-value of 0.016. However, no significant difference was shown between the survival rate according to the p16 and cyclin D1 expressions. On the multivariate analysis that was done with Rb, p16, the tumor size, grade and site, and patient age, the Rb gene expression was the most significant independent prognostic factor with a risk ratio of 3.01 (p=0.04).

Conclusion

The expression of Rb protein was correlated with the histologic grade and overall survival of patients with soft tissue sarcomas.

Citations

Citations to this article as recorded by  
  • Immunohistochemical Expression of p16 and CDK4 in Soft Tissue Tumors
    Mala Sagar, Rita Yadav, Pankaj Deval, Madhu Kumar, Malti K Maurya, Sumaira Qayoom
    Cureus.2023;[Epub]     CrossRef
  • Carcinosarcoma, a Rare Malignant Neoplasm of the Pancreas
    Jaffar Khan, Liang Cheng, Michael G. House, Shunhua Guo
    Current Oncology.2021; 28(6): 5295.     CrossRef
  • Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology
    Yu Jin Kim, Mingi Kim, Hyung Kyu Park, Dan Bi Yu, Kyungsoo Jung, Kyoung Song, Yoon-La Choi
    Laboratory Investigation.2019; 99(9): 1309.     CrossRef
  • Prognostic significance of p16INK4a alteration in soft tissue sarcomas: A meta-analysis
    Gang Lin, Yue Lou
    Indian Journal of Cancer.2017; 54(3): 580.     CrossRef
  • GATA3 Expression Is a Poor Prognostic Factor in Soft Tissue Sarcomas
    Toshiaki Haraguchi, Hiroaki Miyoshi, Koji Hiraoka, Shintaro Yokoyama, Yukinao Ishibashi, Toshihiro Hashiguchi, Koutaro Matsuda, Tetsuya Hamada, Takahiro Okawa, Naoto Shiba, Koichi Ohshima, Ichiro Aoki
    PLOS ONE.2016; 11(6): e0156524.     CrossRef
  • Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?
    Elisabetta Pennacchioli, Giulio Tosti, Massimo Barberis, Tommaso M. De Pas, Francesco Verrecchia, Claudia Menicanti, Alessandro Testori, Giovanni Mazzarol
    Clinical & Experimental Metastasis.2012; 29(7): 757.     CrossRef
  • 10,355 View
  • 65 Download
  • 6 Crossref
Close layer
Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer
Kyung Hee Lee, Myung Soo Hyun, Hoon-Kyo Kim, Hyung Min Jin, Jinmo Yang, Hong Suk Song, Young Rok Do, Hun Mo Ryoo, Joo Seop Chung, Dae Young Zang, Ho-Yeong Lim, Jong Youl Jin, Chang Yeol Yim, Hee Sook Park, Jun Suk Kim, Chang Hak Sohn, Soon Nam Lee
Cancer Res Treat. 2009;41(1):12-18.   Published online March 31, 2009
DOI: https://doi.org/10.4143/crt.2009.41.1.12
AbstractAbstract PDFPubReaderePub
Purpose

Heptaplatin (Sunpla) is a cisplatin derivative. A phase IIb trial using heptaplatin resulted in a 34% response rate with mild nephrotoxicity. We conducted a randomized phase III trial of heptaplatin plus 5-FU compared with cisplatin plus 5-FU in patients with advanced gastric cancer.

Materials and Methods

One hundred seventy-four patients (heptaplatin, n=88; cisplatin, n=86) from 13 centers were enrolled. The eligibility criteria were as follows: patients with pathologically-proven adenocarcinoma, chemonaive patients, or patients who had received only single adjuvant chemotherapy, and who had a measurable or evaluable lesion. On day 1, heptaplatin (400 mg/m2) or cisplatin (60 mg/m2) was given over 1 hour with 5-FU (1 gm/m2) on days 1~5 every 4 weeks.

Results

At the time of survival analysis, the median overall survival was 7.3 months in the 5-FU + heptaplatin (FH) arm and 7.9 months in the 5-FU + cisplatin (FP) arm (p=0.24). Of the FH patients, 34.2% (complete response [CR], 1.3%; partial response [PR], 32.9%) experienced a confirmed objective response compared with 35.9% (CR 0%, PR 35.9%) of FP patients (p=0.78). The median-time-to-progression was 2.5 months in the FH arm and 2.3 months in the FP arm. The incidence of neutropenia was higher with FP (28%) than with FH (16%; p=0.06); grade 3~4 nausea and vomiting were more frequent in the FP than in the FH arm (p=0.01 and p=0.05, respectively). The incidence of increased proteinuria and creatininemia was higher with FH than with FP; however, there was no statistical difference. There were no treatment-related deaths.

Conclusion

Heptaplatin showed similar effects to cisplatin when combined with 5-FU in advanced gastric cancer patients with tolerable toxicities.

Citations

Citations to this article as recorded by  
  • The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
    Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yu
    Cancer Research and Treatment.2025; 57(1): 39.     CrossRef
  • Quantum mechanical approaches and molecular docking analysis of platinum metal-based anticancer drugs Lobaplatin and Heptaplatin targeting cancer DNA - a comparative analysis
    Madhavi Sahadevan, Mullainathan Sundaram, Karunagaran Subramanian
    Chemical Physics Letters.2024; 842: 141191.     CrossRef
  • Cisplatin Resistance in Cancer Therapy: Causes and Overcoming Strategies
    S. Shruthi, K. Bhasker Shenoy
    ChemistrySelect.2024;[Epub]     CrossRef
  • Recent Advances on Pt-Based Compounds for Theranostic Applications
    Giulia Ferrari, Ines Lopez-Martinez, Thomas Wanek, Claudia Kuntner, Diego Montagner
    Molecules.2024; 29(15): 3453.     CrossRef
  • Hallmarks of anticancer and antimicrobial activities of corroles
    Vinay K. Sharma, Yehuda G. Assaraf, Zeev Gross
    Drug Resistance Updates.2023; : 100931.     CrossRef
  • Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases
    Dobrina Tsvetkova, Stefka Ivanova
    Molecules.2022; 27(8): 2466.     CrossRef
  • Second and third-row transition metal compounds containing benzimidazole ligands: An overview of their anticancer and antitumour activity
    Galdina V. Suárez-Moreno, Delia Hernández-Romero, Óscar García-Barradas, Óscar Vázquez-Vera, Sharon Rosete-Luna, Carlos A. Cruz-Cruz, Aracely López-Monteon, Jesús Carrillo-Ahumada, David Morales-Morales, Raúl Colorado-Peralta
    Coordination Chemistry Reviews.2022; 472: 214790.     CrossRef
  • Metalofármacos en la terapia contra el cáncer
    Elizabeth Márquez López, Esmeralda Sánchez Pavón, Rodolfo Peña Rodríguez, Delia Hernández Romero, José M. Rivera Villanueva, Raúl Colorado Peralta, David Morales Morales
    TECNOCIENCIA Chihuahua.2022; 16(3): e1010.     CrossRef
  • Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
    Dan Gibson
    Journal of Inorganic Biochemistry.2021; 217: 111353.     CrossRef
  • Monofunctional Platinum(II) Anticancer Agents
    Suxing Jin, Yan Guo, Zijian Guo, Xiaoyong Wang
    Pharmaceuticals.2021; 14(2): 133.     CrossRef
  • Pt(IV) Prodrugs with NSAIDs as Axial Ligands
    Daniil Spector, Olga Krasnovskaya, Kirill Pavlov, Alexander Erofeev, Peter Gorelkin, Elena Beloglazkina, Alexander Majouga
    International Journal of Molecular Sciences.2021; 22(8): 3817.     CrossRef
  • Multi-action Pt(IV) anticancer agents; do we understand how they work?
    Dan Gibson
    Journal of Inorganic Biochemistry.2019; 191: 77.     CrossRef
  • TOXview: a novel graphical presentation of cancer treatment toxicity profiles
    Lok Lam Ngai, Emil ter Veer, Héctor G. van den Boorn, E. Hugo van Herk, Jessy Joy van Kleef, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
    Acta Oncologica.2019; 58(8): 1138.     CrossRef
  • Photoactivated platinum-based anticancer drugs
    Muhammad Imran, Wagma Ayub, Ian S. Butler, Zia-ur-Rehman
    Coordination Chemistry Reviews.2018; 376: 405.     CrossRef
  • Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis
    Sakura Iizumi, Atsuo Takashima, Kentaro Sakamaki, Satoshi Morita, Narikazu Boku
    Cancer Chemotherapy and Pharmacology.2018; 81(6): 981.     CrossRef
  • An Analytics Approach to Designing Combination Chemotherapy Regimens for Cancer
    Dimitris Bertsimas, Allison O’Hair, Stephen Relyea, John Silberholz
    Management Science.2016; 62(5): 1511.     CrossRef
  • Platinum(iv) anticancer prodrugs – hypotheses and facts
    Dan Gibson
    Dalton Transactions.2016; 45(33): 12983.     CrossRef
  • Platinum(II) carboxylato complexes containing 7-azaindoles as N-donor carrier ligands showed cytotoxicity against cancer cell lines
    Pavel Štarha, Zdeněk Trávníček, Lucia Pazderová, Zdeněk Dvořák
    Journal of Inorganic Biochemistry.2016; 162: 109.     CrossRef
  • VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells
    Sergey A. Shein, Ilya I. Kuznetsov, Tatiana O. Abakumova, Pavel S. Chelushkin, Pavel A. Melnikov, Anna A. Korchagina, Dmitry A. Bychkov, Irina F. Seregina, Mikhail A. Bolshov, Alexander V. Kabanov, Vladimir P. Chekhonin, Natalia V. Nukolova
    Molecular Pharmaceutics.2016; 13(11): 3712.     CrossRef
  • Condensations of single DNA molecules induced by heptaplatin and its chiral isomer
    Hong-Yan Zhang, Yu-Ru Liu, Wei Li, Hui Li, Shuo-Xing Dou, Ping Xie, Wei-Chi Wang, Peng-Ye Wang
    AIP Advances.2014;[Epub]     CrossRef
  • Nanocarriers for delivery of platinum anticancer drugs
    Hardeep S. Oberoi, Natalia V. Nukolova, Alexander V. Kabanov, Tatiana K. Bronich
    Advanced Drug Delivery Reviews.2013; 65(13-14): 1667.     CrossRef
  • Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials
    Kohei Shitara, Junko Ikeda, Tomoya Yokota, Daisuke Takahari, Takashi Ura, Kei Muro, Keitaro Matsuo
    Investigational New Drugs.2012; 30(3): 1224.     CrossRef
  • Cellular interactions of platinum drugs
    Ezequiel Wexselblatt, Eylon Yavin, Dan Gibson
    Inorganica Chimica Acta.2012; 393: 75.     CrossRef
  • What do we know about the reduction of Pt(IV) pro-drugs?
    Ezequiel Wexselblatt, Dan Gibson
    Journal of Inorganic Biochemistry.2012; 117: 220.     CrossRef
  • Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma
    X.-L. Zhang, H.-J. Shi, S.-Z. Cui, Y.-Q. Tang, M.-C. Ba
    European Journal of Surgical Oncology (EJSO).2011; 37(6): 466.     CrossRef
  • The status of platinum anticancer drugs in the clinic and in clinical trials
    Nial J. Wheate, Shonagh Walker, Gemma E. Craig, Rabbab Oun
    Dalton Transactions.2010; 39(35): 8113.     CrossRef
  • 12,253 View
  • 114 Download
  • 26 Crossref
Close layer
Radiation Therapy Combined with (or without) Cisplatin-based Chemotherapy for Patients with Nasopharyngeal Cancer: 15-years Experience of a Single Institution in Korea
Yeon-Sil Kim, Bum-Soo Kim, So-Lyoung Jung, Yeon-Soo Lee, Min-Sik Kim, Dong-Il Sun, Eun-Jung Yoo, Seong-Kwon Mun, Sei-Chul Yoon, Su-Mi Chung, Hoon-Kyo Kim, Seung-Ho Jo, Jin-Hyoung Kang
Cancer Res Treat. 2008;40(4):155-163.   Published online December 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.4.155
AbstractAbstract PDFPubReaderePub
Purpose

This retrospective study was carried out to evaluate the efficacy and toxicity of radiation therapy (RT) with/without cisplatin-based chemotherapy in nasopharyngeal cancer (NPC).

Materials and Methods

One hundred forty six patients with NPC received curative RT and/or cisplatin-based chemotherapy. Thirty-nine patients were treated with induction chemotherapy (IC), including cisplatin and 5-fluorouracil followed by RT. Another 63 patients were treated with concurrent chemoradiotherapy (CCRT) using cisplatin, and 22 patients were treated with IC followed by CCRT. The remaining 22 patients were treated with RT alone.

Results

One hundred four (80.0%) patients achieved complete response (CR), and 23 (17.7%) patients achieved partial response (PR). The patterns of failure were: locoregional recurrences in 21.2% and distant metastases in 17.1%. Five-year overall survival (OS) and progression free survival (PFS) were 50.7% and 45.0%, respectively. Multivariate Cox stepwise regression analysis revealed CR to chemoradiotherapy to be a powerful prognostic factor for OS. CR to chemoradiotherapy and completion of radiation according to the time schedule were favorable prognostic factors for PFS. A comparison of each treatment group (IC → RT vs. CCRT vs. IC → CCRT vs. RT alone) revealed no significant differences in the OS or PFS. However, subgroup analysis showed significant differences in both OS and DFS in favor of the combined chemoradiotherapy group compared with RT alone, for stage IV and T3-4 tumors. Grade 3-4 toxicities were more common in the combined chemoradiotherapy arm, particularly in the CCRT group.

Conclusions

This study was limited in that it was a retrospective study, much time was required to collect patients, and there were imbalances in the number of patients in each treatment group. Combined chemoradiotherapy remarkably prolonged the OS and PFS in subgroup patients with stage IV or T3-4 NPC.

Citations

Citations to this article as recorded by  
  • Effects of SENP1-induced deSUMOylation of STAT1 on proliferation and invasion in nasopharyngeal carcinoma
    Jun Zhang, Guo-lin Tan, Ming Jiang, Tian-sheng Wang, Guo-hui Liu, Shan-shan Xiong, Xiang Qing
    Cellular Signalling.2023; 101: 110530.     CrossRef
  • SEPT9, H4C6, and RASSF1A methylation in nasopharyngeal swabs: A reflection of potential minimally invasive biomarkers for early screening of nasopharyngeal cancer
    Tai Qian, Zhiwei Zhou, Qiongxia Zhang, Yu-Light Liou, Honghao Zhou
    Medicine.2023; 102(50): e36583.     CrossRef
  • MicroRNA-145-5p modulates Krüppel-like factor 5 and inhibits cell proliferation, migration, and invasion in nasopharyngeal carcinoma
    Chien-Han Yuan, Wei-Chi Hsu, A.-Mei Huang, Ben-Chih Yuan, I.-Hung Chen, Chia-An Hsu, Rong-Feng Chen, Yih-Min Chu, Hui-Hui Lin, Hung-Lung Ke
    BMC Molecular and Cell Biology.2022;[Epub]     CrossRef
  • Long-term results of the phase II dose and volume de-escalation trial for locoregionally advanced nasopharyngeal carcinoma
    Fen Xue, Dan Ou, Xiaomin Ou, Xin Zhou, Chaosu Hu, Xiayun He
    Oral Oncology.2022; 134: 106139.     CrossRef
  • Transcription Factor STAT1 Promotes the Proliferation, Migration and Invasion of Nasopharyngeal Carcinoma Cells by Upregulating LINC01160
    Jingang Ai, Guolin Tan, Tiansheng Wang, Wei Li, Ru Gao, Yexun Song, Shanshan Xiong, Xiang Qing
    Future Oncology.2021; 17(1): 57.     CrossRef
  • RETRACTED ARTICLE: Inhibition of PAD4 enhances radiosensitivity and inhibits aggressive phenotypes of nasopharyngeal carcinoma cells
    Hao Chen, Min Luo, Xiangping Wang, Ting Liang, Chaoyuan Huang, Changjie Huang, Lining Wei
    Cellular & Molecular Biology Letters.2021;[Epub]     CrossRef
  • DNA methylation biomarkers for nasopharyngeal carcinoma
    Baoai Han, Xiuping Yang, Po Zhang, Ya Zhang, Yaqin Tu, Zuhong He, Yongqin Li, Jie Yuan, Yaodong Dong, Davood K. Hosseini, Tao Zhou, Haiying Sun, Edwin Wang
    PLOS ONE.2020; 15(4): e0230524.     CrossRef
  • Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Nasopharyngeal Carcinoma Patients after Comprehensive Therapy
    Yueli Tian, Khamis Hassan Bakari, Shanshan Liao, Xiaotian Xia, Xun Sun, Chunxia Qin, Yongxue Zhang, Xiaoli Lan
    Contrast Media & Molecular Imaging.2018; 2018: 1.     CrossRef
  • MiRNA-34a reversed TGF-β-induced epithelial-mesenchymal transition via suppression of SMAD4 in NPC cells
    Guanhong Huang, Ming-yu Du, Hongming Zhu, Nan Zhang, Zhi-Wei Lu, Lu-Xi Qian, Wenjun Zhang, Xiaokang Tian, Xia He, Li Yin
    Biomedicine & Pharmacotherapy.2018; 106: 217.     CrossRef
  • Long non-coding RNA n326322 promotes the proliferation and invasion in nasopharyngeal carcinoma
    Mingyu Du, Teng Huang, Jing Wu, Jia-Jia Gu, Nan Zhang, Kai Ding, Lu-Xi Qian, Zhi-Wei Lu, Wen-Jun Zhang, Xiao-Kang Tian, Xia He, Li Yin
    Oncotarget.2018; 9(2): 1843.     CrossRef
  • GALNT7, a target of miR-494, participates in the oncogenesis of nasopharyngeal carcinoma
    Guo-Hui Nie, Liang Luo, Hong-Fang Duan, Xiao-Qing Li, Mei-Jun Yin, Zhao Li, Wei Zhang
    Tumor Biology.2016; 37(4): 4559.     CrossRef
  • The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis
    Jin Ho Song, Hong-Gyun Wu, Bhum Suk Keam, Jeong Hun Hah, Yong Chan Ahn, Dongryul Oh, Jae Myoung Noh, Hyo Jung Park, Chang Geol Lee, Ki Chang Keum, Jihye Cha, Kwan Ho Cho, Sung Ho Moon, Ji-Yoon Kim, Woong-Ki Chung, Young Taek Oh, Won Taek Kim, Moon-June Ch
    Cancer Research and Treatment.2016; 48(3): 917.     CrossRef
  • MicroRNA-15a Inhibits Proliferation and Induces Apoptosis in CNE1 Nasopharyngeal Carcinoma Cells
    Kang Zhu, Ying He, Cui Xia, Jing Yan, Jin Hou, Demin Kong, Yeye Yang, Guoxi Zheng
    Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics.2016; 24(3): 145.     CrossRef
  • Functional elucidation of miR-494 in the tumorigenesis of nasopharyngeal carcinoma
    Hong-Fang Duan, Xiao-Qing Li, Hong-Yi Hu, Yu-Chi Li, Zhi Cai, Xue-Shuang Mei, Peng Yu, Li-Ping Nie, Wei Zhang, Zhen-Dong Yu, Guo-Hui Nie
    Tumor Biology.2015; 36(9): 6679.     CrossRef
  • Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Patients With Nasopharyngeal Carcinoma Treated With Concurrent Chemoradiotherapy
    Seung Hwan Moon, Joon Young Choi, Hwan Joo Lee, Young-Ik Son, Chung-Hwan Baek, Yong Chan Ahn, Myung-Ju Ahn, Keunchil Park, Byung-Tae Kim
    Clinical and Experimental Otorhinolaryngology.2015; 8(2): 142.     CrossRef
  • MiR-145, a microRNA targeting ADAM17, inhibits the invasion and migration of nasopharyngeal carcinoma cells
    Jing Wu, Li Yin, Ning Jiang, Wen-jie Guo, Jia-jia Gu, Meng Chen, You-you Xia, Jian-zhong Wu, Dan Chen, Jian-feng Wu, De-jun Wang, Dan Zong, Nan Zhang, Kai Ding, Teng Huang, Xia He
    Experimental Cell Research.2015;[Epub]     CrossRef
  • miR‐539 induces cell cycle arrest in nasopharyngeal carcinoma by targeting cyclin‐dependent kinase 4
    Ling‐yan Lv, Yu‐zhi Wang, Qian Zhang, Hong‐rui Zang, Xing‐jie Wang
    Cell Biochemistry and Function.2015; 33(8): 534.     CrossRef
  • Chemotherapy of Head and Neck Cancer
    Chang Ki Yeo
    Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2014; 57(5): 291.     CrossRef
  • MicroRNA‐320a inhibits cell proliferation, migration and invasion by targeting BMI‐1 in nasopharyngeal carcinoma
    Xiaoming Qi, Jianqiang Li, Changbo Zhou, Chunlei Lv, Min Tian
    FEBS Letters.2014; 588(20): 3732.     CrossRef
  • IMRT with Simultaneous Integrated Boost and Concurrent Chemotherapy for Nasopharyngeal Cancer: Plan Evaluation and Treatment Outcome
    J. W. Kim, J. H. Cho, K. C. Keum, J. H. Kim, G. E. Kim, J. Y. Lee, S. K. Kim, C. G. Lee
    Japanese Journal of Clinical Oncology.2012; 42(12): 1152.     CrossRef
  • Does the prognosis of nasopharyngeal cancer differ among endemic and non-endemic regions?
    Senem Demirci, Serra Kamer, Gulsen Kara, Ozgur Yildirim, Mustafa Esassolak
    Acta Oto-Laryngologica.2011; 131(8): 852.     CrossRef
  • miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion
    Hongping Xia, Samuel S. Ng, Songshan Jiang, William K.C. Cheung, Johnny Sze, Xiu-Wu Bian, Hsiang-fu Kung, Marie C. Lin
    Biochemical and Biophysical Research Communications.2010; 391(1): 535.     CrossRef
  • 10,890 View
  • 67 Download
  • 22 Crossref
Close layer
Case Reports
Sequential Responses of Adenocarcinoma of the Lung to Erlotinib after Gefitinib in Never Smoker Korean Woman
Hoon-Kyo Kim, Myeong Im Ahn, Jinyoung Yoo, Chi Hong Kim, Hong-Jun Yang, Byoung Yong Shim
Cancer Res Treat. 2007;39(1):37-39.   Published online March 31, 2007
DOI: https://doi.org/10.4143/crt.2007.39.1.37
AbstractAbstract PDFPubReaderePub

A patient with adenocarcinoma of the lung was treated sequentially using two kinds of EGFR tyrosine kinase inhibitors, gefitinib and erlotinib. The patient was a 73-year-old female who received gefitinib as a second line treatment, which resulted in a partial response with response duration of 6 months. After progression of the disease, the patient received erlotinib, which resulted in partial response again with response duration of 11.5 months. This observation suggests that treatment with erlotinib may be effective in patients who develop progressive disease after a primary treatment with gefitinib following an initial response.

Citations

Citations to this article as recorded by  
  • Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature
    Navneet Singh
    World Journal of Clinical Oncology.2014; 5(5): 858.     CrossRef
  • Successful Rechallenge with Gefitinib for an Initial Erlotinib-Responder with Advanced Lung Adenocarcinoma
    Sung Chul Hong, Yun Su Sim, Jin Hwa Lee, Yon Ju Ryu, Jung Hyun Chang
    Tuberculosis and Respiratory Diseases.2011; 71(4): 286.     CrossRef
  • 10,081 View
  • 61 Download
  • 2 Crossref
Close layer
Hypersensitivity Reactions to Oxaliplatin
Kyoung-Hwan Lee, Yong Jai Park, Eun Sun Kim, Hui Jeong Hwang, Byoung Yong Shim, Hoon-Kyo Kim
Cancer Res Treat. 2006;38(4):240-241.   Published online December 31, 2006
DOI: https://doi.org/10.4143/crt.2006.38.4.240
AbstractAbstract PDFPubReaderePub

Oxaliplatin is a third-generation platinum compound that is used as a single agent and in combination with fluorouracil (5-FU) to treat colorectal and gastric carcinoma. The patients treated with oxaliplatin may develop hypersensitivity and idiosyncratic reactions, although these complications are known to be rare. We report here on two patients who suffered with metastatic colorectal cancer and who underwent palliative combination chemotherapy with oxaliplatin; they then developed hypersensitivity reactions to oxaliplatin. The first case had an anaphylatic reaction immediately after the beginning of the 7th to 8th cycle infusion of oxaliplatin. The second case developed repeated febrile episodes from the 4th to 8th cycles of oxaliplatin infusion. With the increasing use of oxaliplatin in clinical practice, we are now encountering an increasing incidence of suspected hypersensitivity reactions. Physicians should keep their eyes wide open and carefully observe for the clinical manifestations of these hypersensitivity reactions.

Citations

Citations to this article as recorded by  
  • A case report of an adverse drug reaction with a combination of oxaliplatin and perindopril
    Christina Okello
    Journal of Case Reports and Images in Oncology.2022; 7(1): 1.     CrossRef
  • Delayed hypersensitivity to oxaliplatin in a nigerian patient with colorectal cancer—A case report
    Usman M Aliyu, Charles O Okwonna
    Journal of Oncology Pharmacy Practice.2021; 27(5): 1258.     CrossRef
  • Rare presentation of subglottic soft-tissue swelling following FOLFOX therapy in a patient with metastatic oesophageal cancer
    Siva Naga S Yarrarapu, Austin B Govero, Faeq R Kukhon, Devang K Sanghavi
    BMJ Case Reports.2021; 14(4): e240938.     CrossRef
  • Atypical presentation of fever as hypersensitivity reaction to oxaliplatin
    Arushi Khurana, Demytra Mitsis, Gurukripa N Kowlgi, Lisa M Holle, Jessica M Clement
    Journal of Oncology Pharmacy Practice.2016; 22(2): 319.     CrossRef
  • Hypersensitivity Reactions to Oxaliplatin: Clinical Features and Risk Factors in Koreans
    Mi-Yeong Kim, Sung-Yoon Kang, Suh-Young Lee, Min-Suk Yang, Min-Hye Kim, Woo-Jung Song, Sae-Hoon Kim, Yo-Jung Kim, Keun-Wook Lee, Sang-Heon Cho, Kyung-Up Min, Jong-Seok Lee, Jee-Hyun Kim, Yoon-Seok Chang
    Asian Pacific Journal of Cancer Prevention.2012; 13(4): 1209.     CrossRef
  • Revisión de las reacciones de hipersensibilidad a antineoplásicos
    S. Cortijo-Cascajares, M.J. Jiménez-Cerezo, A. Herreros de Tejada
    Farmacia Hospitalaria.2012; 36(3): 148.     CrossRef
  • 7,853 View
  • 98 Download
  • 6 Crossref
Close layer
Original Articles
The Efficacy and Safety of Padexol® (Paclitaxel) and Cisplatin for Treating Advanced Non-small Cell Lung Cancer
Hoon-Kyo Kim, Jun Suk Kim, Hun Mo Ryoo, Dong Gun Shin, Byoung Young Shim, Kyong Hwa Park, Sung Hwa Bae, Chi Hong Kim
Cancer Res Treat. 2006;38(2):66-71.   Published online April 30, 2006
DOI: https://doi.org/10.4143/crt.2006.38.2.66
AbstractAbstract PDFPubReaderePub
Purpose

The authors conducted a multicenter study to evaluate the efficacy and safety of combination chemotherapy with Padexol® and cisplatin for treating patients with advanced non-small cell lung cancer (NSCLC).

Materials and Methods

From November 2003 to April 2005, 42 chemo-naive patients with advanced NSCLC were enrolled into this study from 4 hospitals. The treatment consisted of Padexol® 175 mg/m2 as a 3-hr infusion, and this was followed by cisplatin 75 mg/m2 administered as an intravenous infusion with standard premedication. The treatment was repeated every 3 weeks.

Results

Among the 42 patients (pts), 33 pts were evaluable for response. On the per protocol analysis, 1 patient (pt) (3.0%) achieved complete response (CR), 17 pts (51.5%) achieved partial response (PR), 6 pts (18.2%) achieved stable disease (SD), and 9 pts (27.3%) progressed; therefore, the overall response rate was 54.6% (95% CI: 37.6~71.5%). On the intention-to-treat analysis, 1 pt (2.4%) achieved CR, 18 pts (42.9%) achieved PR, 11 pts (26.2%) achieved SD, and 9 pts (21.4%) progressed; therefore, the overall response rate was 45.2% (95% CI: 30.2~60.3%). The response, as evaluated by the investigators, was independently reviewed by 2 external radiologists and it was as follows; 13 PR (43.3%), 14 SD (46.7%) and 3 progressive disease (10%). The median duration of response was 5.9 months. The median follow-up duration was 10.3 months (range: 1.3 to 22.1 months). The median time to progression was 5.8 months (95% CI: 4.7 to 7.4 months). The median survival time on the intention-to-treat analysis was 10.5 months (95% CI: 8.1 to 18.8 months). The most common grade 3 or 4 hematologic toxicities were neutropenia (26/180 cycles, 14.4%), anemia (7/180 cycles, 3.9%) and febrile neutropenia (2/180 cycles, 1.1%). The most frequent grade 3 or 4 non-hematologic toxicities were nausea (14/42 patients, 14.3%), anorexia (3/42 patients, 7.1%) and myalgia (3/42 patients, 7.1%).

Conclusion

The authors observed that Padexol® was as good as the other paclitaxel (Taxol® or Genexol®) formulations when combined with cisplatin for treating patients with advanced NSCLC.

Citations

Citations to this article as recorded by  
  • The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China
    Puyuan Xing, Yixiang Zhu, Ling Shan, Sipeng Chen, Xuezhi Hao, Junling Li
    Oncotarget.2017; 8(50): 87442.     CrossRef
  • Efficacy and Safety of Weekly Low Dose Paclitaxel and Cisplatin as First Line Therapy in Advanced NSCLC of Elderly Patients
    Jung Ho Lee, Mi Hye Kwon, Ji Hyun Jeoung, Go Eun Lee, Eu Gene Choi, Moon Jun Na, Hyun Min Cho, Young Jin Kim, Weon Kuu Chung, Young Jun Cho, Ji Woong Son
    Journal of Lung Cancer.2007; 6(2): 85.     CrossRef
  • 9,937 View
  • 49 Download
  • 2 Crossref
Close layer
The Safety and Efficacy of Second-line Single Docetaxel (75 mg/m2) Therapy in Advanced Non-Small Cell Lung Cancer Patients who were Previously Treated with Platinum-based Chemotherapy
Byoung Yong Shim, Chi Hong Kim, So Hyang Song, Meyung Im Ahn, Eun Jung Hong, Sung Whan Kim, Suzy Kim, Min Seop Jo, Deog Gon Cho, Kyu Do Cho, Jinyoung Yoo, Hoon-Kyo Kim
Cancer Res Treat. 2005;37(6):339-343.   Published online December 31, 2005
DOI: https://doi.org/10.4143/crt.2005.37.6.339
AbstractAbstract PDFPubReaderePub
Purpose

When used in the second-line setting, single-agent chemotherapy has produced response rates of more than 10% or median survival times greater than 4 months. We studied the safety and efficacy of using second-line single docetaxel (75 mg/m2) for advanced NSCLC patients who were previously treated with platinum-based chemotherapy in Korea.

Materials and Methods

Thirty-three patients with advanced NSCLC received chemotherapy from May 2002 to January 2005. We retrospectively reviewed the charts of these patients. The patients received 75 mg/m2 of doxetaxel on day 1 and this was repeated at 3-week intervals.

Results

The median age was 63 years (range: 42~77 years); 16 patients had adenocarcinoma and 8 patients had squamous cell carcinoma. The median number of cycles was 4 (range: 1~7 cycles). Of the 33 patients, 6 patients had partial responses, 13 patients had stable disease and 14 patients had progressive disease. The response rate was 18.2%. The median overall survival was 11 months (range: 7~15 months), and the median progression free survival was 5 months (range: 3~7 months). The median response duration was 5 months (range: 4~9 months). A total of 137 cycles were evaluated for toxicity. We observed grade 3 or 4 neutropenia in 79 cycles (57.6%), grade 3 or 4 leukopenia in 46 cycles (33.6%), and grade 3 febrile neutropenia in 2 cycles (1.5%). The median nadir day was day 9 (range: day 5~19), and the median number of G-CSF injections was 2 (range: 0~6). The most common non-hematologic toxicities were myalgia/arthralgia and neurotoxicity, but any grade 3 or 4 non-hematologic toxicity was not observed. The major toxicity of this therapy was neutropenia. The absolute neutrophil count decreased relatively rapidly, but neutropenic fever or related infection was rare. There were no treatment-related deaths.

Conclusion

These results revealed a satisfactory response rate (18.2%) with using docetaxel as the second-line chemotherapy for NSCLC. The second-line docetaxel was an active and well-tolerated regimen in patients with advanced NSCLC pretreated with platinum-based chemotherapy.

Citations

Citations to this article as recorded by  
  • Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study
    Yongchang Zhang, Lianxi Song, Liang Zeng, Yi Xiong, Li Liu, Chunhua Zhou, Haiyan Yang, Zhan Wang, Qing Xia, Wenjuan Jiang, Qinqin Xu, Nong Yang
    BMC Cancer.2022;[Epub]     CrossRef
  • Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer
    JoungSoon Jang, Hoon-Kyo Kim, Byoung Chul Cho, Kyung Hee Lee, Hwan-Jung Yun, In Sook Woo, Hong Suk Song, Hun-Mo Ryoo, Chi-Hong Kim, Der-Sheng Sun, Jong Wook Shin
    Cancer Chemotherapy and Pharmacology.2017; 79(5): 873.     CrossRef
  • Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy—a systematic review
    Ricardo Fernandes, Sasha Mazzarello, Habeeb Majeed, Stephanie Smith, Risa Shorr, Brian Hutton, Mohammed FK Ibrahim, Carmel Jacobs, Michael Ong, Mark Clemons
    Supportive Care in Cancer.2016; 24(4): 1583.     CrossRef
  • Weekly Low-Dose Docetaxel for Salvage Chemotherapy in Pretreated Elderly or Poor Performance Status Patients with Non-small Cell Lung Cancer
    Keun-Wook Lee, Joo Han Lim, Jee Hyun Kim, Choon-Taek Lee, Jong Seok Lee
    Journal of Korean Medical Science.2008; 23(6): 992.     CrossRef
  • Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients
    Yoon Ho Ko, Myung Ah Lee, Yeong Seon Hong, Kyung Shik Lee, Hyun Jin Park, Ie Ryung Yoo, Yeon Sil Kim, Young Kyoon Kim, Keon Hyun Jo, Young Pil Wang, Kyo Young Lee, Jin Hyoung Kang
    The Korean Journal of Internal Medicine.2007; 22(3): 178.     CrossRef
  • 10,563 View
  • 68 Download
  • 5 Crossref
Close layer
Oxaliplatin/5-FU without Leucovorin Chemotherapy in Metastatic Colorectal Cancer
Byoung Yong Shim, Kang Moon Lee, Hyeon-Min Cho, Hyun Jin Kim, Hong Joo Cho, Jinmo Yang, Jun-Gi Kim, Hoon-Kyo Kim
Cancer Res Treat. 2005;37(4):212-215.   Published online August 31, 2005
DOI: https://doi.org/10.4143/crt.2005.37.4.212
AbstractAbstract PDFPubReaderePub
Purpose

Fluorouracil (5-FU) and leucovorin combination therapy have shown synergistic or additive effect against advanced colorectal cancer, but the frequency of mucositis and diarrhea is increased. Most previous studies have used high dose leucovorin (300~500 mg/m2). However, some studies of oxaliplatin and 5-FU with low-dose or high-dose leucovorin in Korea have shown similar response rates. Therefore, we studied the necessity of leucovorin and evaluated the objective tumor response rates and toxicities of a regimen of oxaliplatin and 5-FU without leucovorin every 2 weeks in metastatic colorectal cancer patients.

Materials and Methods

Twenty-four patients with metastatic colorectal cancer were enrolled between January 2002 and March 2003. Patients received 85 mg/m2 of oxaliplatin on day 1, a bolus 5-FU 400 mg/m2 on day 1 and a continuous 5-FU infusion at 600 mg/m2/ 22 hours days 1 and 2, every 2 weeks.

Results

Of the 24 patients treated, 17 patients received previous 5FU with leucovorin and/or other chemotherapy. Three patients could not be evaluated. Five partial responses were observed with overall response rate of 21% (n=24). Of the previous chemotherapy group (n=17), 4 partial responses were observed with response rate of 24%. Median overall survival was 18 months (range 4~32 months) and median progression free survival was 4 months (range 2~6 months). This regimen was well tolerated and only 1 grade 3 anemia was observed.

Conclusion

Oxaliplatin/5-FU combination therapy without leucovorin achieved a relatively high response rate even in patients resistant to the previous 5-FU chemotherapy, and toxicity was minimal.

Citations

Citations to this article as recorded by  
  • Clinicopathological Features and Oncological Outcomes of Early and Late Recurrence in Stage III Colorectal Cancer Patients after Adjuvant Oxaliplatin-Based Therapy
    Yu-Tang Chang, Hsiang-Lin Tsai, Yen-Cheng Chen, Ching-Chun Li, Ching-Wen Huang, Po-Jung Chen, Wei-Chih Su, Tsung-Kun Chang, Yung-Sung Yeh, Tzu-Chieh Yin, Jaw-Yuan Wang, Weiren Luo
    Journal of Oncology.2023; 2023: 1.     CrossRef
  • Targeting the SPHK1/HIF1 Pathway to Inhibit Colorectal Cancer Stem Cells Niche
    Saeideh Gholamzadeh Khoei, Hamid Sadeghi, Fateme Karimi Dermani
    Journal of Gastrointestinal Cancer.2020; 51(2): 716.     CrossRef
  • Efficacy of 5-FU or Oxaliplatin Monotherapy over Combination Therapy in Colorectal Cancer
    Maria Toloudi, Panagiotis Apostolou, Ioannis Papasotiriou
    Journal of Cancer Therapy.2015; 06(04): 345.     CrossRef
  • Gene Expression Changes in Colorectal Cancer during Metronomic Chemotherapy and High-Concentration Drug Administration
    Panagiotis Apostolou, Maria Toloudi, Irene Kalliara, Vasiliki Kipourou, Ioanna Tourna, Ioannis Papasotiriou
    Journal of Cancer Therapy.2015; 06(08): 679.     CrossRef
  • 10,467 View
  • 45 Download
  • 4 Crossref
Close layer
Expression of c-kit and p53 in Non-small Cell Lung Cancers
Jinyoung Yoo, Chi Hong Kim, So Hyang Song, Byoung Yong Shim, Youn Ju Jeong, Meyung Im Ahn, Sung Whan Kim, Deog Gon Cho, Min Seop Jo, Kyu Do Cho, Hong Joo Cho, Hoon-Kyo Kim
Cancer Res Treat. 2004;36(3):167-172.   Published online June 30, 2004
DOI: https://doi.org/10.4143/crt.2004.36.3.167
AbstractAbstract PDFPubReaderePub
Purpose

Increasing experimental evidence indicates that abnormal expression of c-kit may be implicated in the pathogenesis of a variety of solid tumors. It has been reported that over 70% of small cell lung cancer (SCLC) contain the c-kit receptor. In the present study, a c-kit analysis has been extended to non-small cell lung cancer (NSCLC). The expressions of p53, vascular endothelial growth factor (VEGF) and cd34, in addition to c-kit, were evaluated to investigate the correlations between these proteins and to determine their potential relationships with the clinicopathological data.

Materials and Methods

Paraffin-embedded tumor sections, obtained from 147 patients with NSCLC, were immunohistochemically investigated using anti-c-kit, anti-p53, anti-VEGF and anti-cd34 antibodies.

Results

c-kit was expressed in 40 (27%) of the tumors examined: 27% of the adenocarcinomas, 27% of the squamous cell carcinomas and 29% of the undifferentiated carcinomas. p53 and VEG F immunoreactivities were present in 107 (73%) and 110 (75%) carcinomas, respectively. Anti-cd34 was negative in all samples. No associations were established among these proteins. The c-kit, however, showed a strong correlation with the T factor: T1 (n=11), 0%; T2 (n=49), 16% and T3 (n=87), 37% (p=.006).

Conclusion

It is suggested that in NSCLC c-kit is expressed relatively frequently and may become a therapeutic target for the patients with inoperable or recurrent c-kit positive tumors. The alterations in p53 probably constitute an early event, whereas the activated c-kit may contribute to tumor progression.

Citations

Citations to this article as recorded by  
  • Clinical and Prognostic Significance of CD117 in Non-Small Cell Lung Cancer: A Systemic Meta-Analysis
    Ying Su, Ru Chen, Zhongcheng Han, Rong Xu, Lili Ma, Reyina Wufuli, Hongbo Liu, Fang Wang, Lei Ma, Rui Chen, Jiang Liu
    Pathobiology.2021; 88(4): 267.     CrossRef
  • A review of predictive, prognostic and diagnostic biomarkers for non-small-cell lung cancer: towards personalised and targeted cancer therapy
    Ernest Osei, Julia Lumini, Dinindu Gunasekara, Beverley Osei, Akua Asare, Raymond Laflamme
    Journal of Radiotherapy in Practice.2020; 19(4): 370.     CrossRef
  • Design, synthesis and anti-cancer activity of pyrrole-imidazole polyamides through target-downregulation of c-kit gene expression
    Mi Zhang, Jing Liang, Shi-Kun Jiang, Ling Xu, Yan-Ling Wu, Annoor Awadasseid, Xiao-Yin Zhao, Xu-Qiong Xiong, Hiroshi Sugiyama, Wen Zhang
    European Journal of Medicinal Chemistry.2020; 207: 112704.     CrossRef
  • Relative influence of c-Kit expression and epidermal growth factor receptor gene amplification on survival in patients with non-small cell lung cancer
    HUI XIAO, JUAN WANG, YANAN LIU, LI LI
    Oncology Letters.2014; 8(2): 582.     CrossRef
  • Protein Kinase C-δ–Mediated Recycling of Active KIT in Colon Cancer
    Misun Park, Won Kyu Kim, Meiying Song, Minhee Park, Hyunki Kim, Hye Jin Nam, Sung Hee Baek, Hoguen Kim
    Clinical Cancer Research.2013; 19(18): 4961.     CrossRef
  • 9,135 View
  • 62 Download
  • 5 Crossref
Close layer
Cancer Res Treat : Cancer Research and Treatment
© Korean Cancer Association.
Close layer
TOP